Indian Defence Review on MSN
New Malaria Treatment Could Save Hundreds of Thousands of Lives
A new malaria drug, GanLum, developed by Swiss pharmaceutical giant Novartis, is showing high cure rates and the potential to ...
Zacks Investment Research on MSN
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
Novartis NVS reported positive top-line data from a late-stage study of its investigational new malaria treatment candidate, ...
The study of GanLum (KLU156) – a combination of novel drug ganaplacide with established antimalarial lumefantrine – showed ...
In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...
In what experts are calling a breakthrough in the global fight against malaria, a new next-generation drug candidate — GanLum ...
An experimental drug was effective against malaria in a new study, potentially offering a much-needed buffer against the ...
A new malaria drug, Ganaplacide/Lumefantrine, shows over 97% cure rates in trials. This treatment is effective even where ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Request To Download Free Sample of This Strategic Report @ Market Overview: The global malaria diagnostics market was valued at $728,870 thousand in 2018 and is projected to reach $1,085,106 thousand ...
To tackle antimicrobial resistance, the ICMR is designing a framework for standardized pathogen testing across India. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback